anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Theravance Biopharma · conference-presentation

Theravance Biopharma | Investor Conference Presentation Deck | 44 slides

44 pages · 6 arc beats · 3 loops

Conference-Presentation Download JSON
Unlock

Theravance Biopharma | Investor Conference Presentation Deck | 44 slides

Theravance Biopharma · 2022-11
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

6
coverage by narrative range · generated from this deck JSON
Narrative range 17 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Agitate (Make it worse) 4 slides 100% 4/4 slides 100% 4/4 slides · 18 hits
— 0/4 slides
25% 1/4 slides · 2 hits 25% 1/4 slides 100% 4/4 slides 100% 4/4 slides Solution (Provide relief) 7 slides 100% 7/7 slides 100% 7/7 slides · 29 hits
— 0/7 slides
— 0/7 slides
28.6% 2/7 slides 100% 7/7 slides · 10 hits 42.9% 3/7 slides Key Takeaways 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides · 4 hits 50% 1/2 slides KPI Overview 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides
— 0/2 slides
Conclusion 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits
— 0/1 slides

Slide inventory

44
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
Poster #117front_matter
Open slide detail
03
other
Open slide detail
04
transition
Open slide detail
05
frame_problem
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
06
The slide uses anatomical diagrams to illustrate the spread of alpha-synuclein (labeled 'α') across the nervous system for three different neurodegenerative concompare_peers
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
07
The slide uses a biological process diagram to explain the mechanism of action for midodrine and droxidopa in the context of autonomic disorders.present_framework
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
08
Includes a screenshot of a BMC Neurology paper and a bar chart showing subgroup analysis of OHSA scores.diagnose_problem
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
09
The slide uses a biological process diagram to explain how different drugs (agonists, precursors, reuptake inhibitors) affect sympathetic signaling to blood vespresent_framework
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
10
The slide uses a biological process diagram to explain the drug's mechanism of action.present_solution
Open slide detailBeat · Solution (Provide relief)
11
The slide uses a process flow diagram to show how patients transition from Study 0169 to 0170.present_framework
Open slide detailBeat · Solution (Provide relief)
12
The slide shows a significant increase in Norepinephrine levels with Ampreloxetine treatment compared to placebo.analyze_data
Open slide detailBeat · Solution (Provide relief)
13
Study 0169 data showing significant increases in Norepinephrine and decreases in DHPG across three patient cohorts.analyze_data
Open slide detailBeat · Solution (Provide relief)Loop · Aha Moment
14
The chart illustrates a worsening of blood pressure in the placebo group compared to the treatment group.analyze_data
Open slide detailBeat · Solution (Provide relief)Loop · Before After
15
The slide uses a bar chart with error bars to show treatment effects. 'Worsening' is indicated by a downward arrow on the right.analyze_data
Open slide detailBeat · Solution (Provide relief)Loop · Before After
16
Includes a footer with abbreviations for BP, DHPG, MSA, NE, and nOH.summarize
Open slide detailBeat · Solution (Provide relief)
17
Poster #106front_matter
Open slide detail
18
other
Open slide detail
19
The slide highlights the failure of Study 0169 and the subsequent early termination of Study 0170.illustrate_case
Open slide detail
20
The slide outlines a complex clinical trial structure involving rollovers from Study 0169 and de novo participants, leading into a randomized withdrawal period.present_framework
Open slide detail
21
The slide uses a flow diagram to illustrate study design and participant disposition.present_framework
Open slide detail
22
The slide provides a standard 'Table 1' style clinical trial baseline characteristic summary.analyze_data
Open slide detail
23
The slide shows patient counts and percentages for study completion and various reasons for discontinuation.analyze_data
Open slide detail
24
The slide uses a forest plot to visualize the odds ratio (0.60) with a 95% confidence interval (0.27, 1.29) crossing the null value of 1.0.analyze_data
Open slide detail
25
Uses a visual comparison to explain the biological mechanism of action.diagnose_problem
Open slide detail
26
The slide highlights the MSA subgroup with a blue box, suggesting a focus on this specific finding.analyze_data
Open slide detailBeat · KPI Overview
27
The slide uses forest plots to compare treatment effects (ampreloxetine vs placebo) across different patient populations (Overall, MSA, PD, PAF).analyze_data
Open slide detailBeat · KPI Overview
28
The slide includes a table of adverse events and bulleted takeaways regarding clinical safety parameters.analyze_data
Open slide detail
29
The slide includes a list of authors for a related longitudinal analysis.summarize
Open slide detail
30
Poster #4front_matter
Open slide detail
31
front_matter
Open slide detail
32
The slide uses a bulleted list to frame the clinical trial narrative from failure to a focused subgroup opportunity.summarize
Open slide detail
33
The slide uses a biological mechanism diagram to illustrate the drug's effect on norepinephrine reuptake.diagnose_problem
Open slide detail
34
The slide outlines a clinical trial program involving three studies (0169, 0170, 0171) with specific eligibility criteria and endpoints for a longitudinal analypresent_framework
Open slide detail
35
The diagram tracks patient enrollment, completion, and reasons for discontinuation at each stage.summarize
Open slide detail
36
The diagram uses a standard CONSORT-style flow chart structure to track patient enrollment, completion, and withdrawal reasons.illustrate_case
Open slide detail
37
The slide provides a summary of patient characteristics to demonstrate baseline comparability.analyze_data
Open slide detail
38
The chart uses a split-axis design to represent different study periods (Study 0169 and 0170).analyze_data
Open slide detail
39
The chart uses a split-axis design to represent three distinct study phases (0169, 0170 OL, 0170 RW).analyze_data
Open slide detail
40
The chart uses a forest plot format to visualize confidence intervals for multiple clinical endpoints.analyze_data
Open slide detail
41
The chart uses a randomized withdrawal (RW) design to isolate the effect of drug discontinuation.analyze_data
Open slide detail
42
The slide includes a footnote defining abbreviations and study parameters.analyze_data
Open slide detail
43
Includes a footer with abbreviations for MSA, nOH, OHSA, and SBP.summarize
Open slide detail
44
The slide uses a tree metaphor for the study name 'CYPRESS'.present_framework
Open slide detail